| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 7, 2020
South San Francisco, CA, July 7, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed biopharmaceutical industry...
-
Jun 11, 2020Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)
South San Francisco, CA, June 11, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that two poster presentations supporting the...
-
Jun 1, 2020More than 1,140 patients randomized and topline results expected in second half 2020
South San Francisco, CA, June 1, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported completion of enrollment and randomization in its...
-
May 27, 2020
South San Francisco, CA, May 27, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive...
-
May 18, 2020Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations
South San Francisco, CA, May 18, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that two abstracts and scientific presentations...